- Home
- RNAZ vs IMCC Comparison
RNAZ vs IMCC Comparison
Compare RNAZ & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- IMCC
- Stock Information
- Founded
- RNAZ 2016
- IMCC 1980
- Country
- RNAZ United States
- IMCC Israel
- Employees
- RNAZ N/A
- IMCC N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- RNAZ Health Care
- IMCC Health Care
- Exchange
- RNAZ Nasdaq
- IMCC Nasdaq
- Market Cap
- RNAZ 7.2M
- IMCC 7.5M
- IPO Year
- RNAZ 2021
- IMCC N/A
- Fundamental
- Price
- RNAZ $0.53
- IMCC $1.58
- Analyst Decision
- RNAZ Strong Buy
- IMCC
- Analyst Count
- RNAZ 1
- IMCC 0
- Target Price
- RNAZ $20.00
- IMCC N/A
- AVG Volume (30 Days)
- RNAZ 16.6M
- IMCC 8.3K
- Earning Date
- RNAZ 05-14-2025
- IMCC 03-31-2025
- Dividend Yield
- RNAZ N/A
- IMCC N/A
- EPS Growth
- RNAZ N/A
- IMCC N/A
- EPS
- RNAZ N/A
- IMCC N/A
- Revenue
- RNAZ N/A
- IMCC $37,551,778.00
- Revenue This Year
- RNAZ $180.81
- IMCC $22.59
- Revenue Next Year
- RNAZ N/A
- IMCC $32.86
- P/E Ratio
- RNAZ N/A
- IMCC N/A
- Revenue Growth
- RNAZ N/A
- IMCC 10.71
- 52 Week Low
- RNAZ $0.43
- IMCC $1.50
- 52 Week High
- RNAZ $66.33
- IMCC $8.10
- Technical
- Relative Strength Index (RSI)
- RNAZ 28.52
- IMCC 36.99
- Support Level
- RNAZ $0.43
- IMCC $1.50
- Resistance Level
- RNAZ $0.61
- IMCC $1.84
- Average True Range (ATR)
- RNAZ 0.17
- IMCC 0.14
- MACD
- RNAZ 0.21
- IMCC -0.01
- Stochastic Oscillator
- RNAZ 8.24
- IMCC 16.33
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.